MTT法在非小细胞肺癌优化治疗方案中的应用

Application of optimizing therapeutic regimen for non-small cell lung cancer with MTT assay

目的:通过非小细胞肺癌体外原代细胞的培养,对其常用的化疗药物进行敏感性检测,探讨不同化疗药物之间的敏感性差异,筛选出最佳的化疗药物或联合化疗方案。方法:应用MTT显色分析法测定40例非小细胞肺癌实体瘤标本对9种化疗药物及其组成的联合化疗方案的敏感性或耐药性,并比较结果。结果:非小细胞肺癌化疗敏感性个体差异较大。联合化疗药物的敏感性明显优于单药,P=0.038。各药物平均抑制率由高到低的顺序依次为DDP+HCPT>DDP+VP16>HCPT>DDP+NVB>DDP+ADM+IFO>ADM>CTX+ADM+VCR>DDP>NVB>VP16>CBP>IFO>VP16+CBP>VCR>CTX。无论是单药组间比较,还是联合药物组间比较,其敏感性的差异均有显著差异,均P<0.01。结论:体外肿瘤细胞药敏试验对临床肿瘤化疗用药有很强的指导性,并能发现耐药病例。对非小细胞肺癌患者进行化疗时,应尽量选择联合用药方案。

To investigate the different sensitivities of commonly used chemotherapeutic drugs on nonsmall cell lung cancer（NSCLC） by the method of primary culture of NSCLC cells, and to screen the best chemotherapeutic drugs or combined drugs. Methods： The drug sensitivity or resistance of 40 NSCLC samples to 9 chemotherapeutic drugs and combined chemotherapy were detected by MTT colorimetric assay, and compared the results. Results：The individual chemosensitivity was comparatively different. The chemosensitivity of combined drugs was apparently superior to single drugs, P = 0. 038. The sequence for the average inhibition ratio of drugs was DDP ＋ HCPT 〉 DDP ＋ VP16 〉 HCPT 〉 DDP ＋ NVB 〉 DDP ＋ ADM ＋ IFO 〉 ADM 〉 CTX ＋ ADM ＋ VCR 〉 DDP 〉 NVB 〉 VP16 〉 CBP 〉 IFO 〉 VP16 ＋ CBP 〉 VCR 〉 CTX. There were significant differences in sensitivity among the single drug groups and among the combined drug groups, all P 〈 0.01. Conclusion： The tumour chemosensitivity test in vitro gave some prediction and guidances for the clinical chemotherapy, and it could discover the drug resisting cases. The combined chemotherapy should be selected for NSCLC patients.